Trending Now
SPY takes a bearish dip for markets to tank
Futures have taken a downturn following a steel and aluminum tariff announcement.
This makes one biased toward a...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Oncolytics Bioetch Inc. (NASDAQ: ONCY) Presents Enrolment Updates of Phase 1/2...
Oncolytics Bioetch Inc. (NASDAQ: ONCY) has presented a recruitment update in the Phase 1/2 GOBLET trial in a poster at the 2022 American Society...
MAKE IT MODERN
LATEST REVIEWS
Momentum Stock Focus: Clubhouse Media Group (OTCMKTS:TONJ) and the Future of...
Tongji Healthcare Group Inc (OTCMKTS:TONJ) has become Clubhouse Media Group, and has become one of the most interesting stocks trading on the...
MAKE IT MODERN
PERFORMANCE TRAINING
The Bull Opportunity Ahead in Telehealth Stocks (TDOC, ONEM, ISWH, AMWL)
Few trends are as easily identifiable as the structural opportunity in the telehealth space. We have undergone a transformative experience as a...
Denali Therapeutics Inc (NASDAQ:DNLI) Releases Major Update On Phase 1b Of Its RIPK1 Program
Denali Therapeutics Inc (NASDAQ:DNLI) provided an update on Phase 1b trial findings involving its RIPK1 small molecule inhibitor used to target ALS and Alzheimer’s...
Tauriga Sciences Inc (OTCMKTS:TAUG) Could React on New Aegea Rapid Test News
It’s tough to imagine a less likely combination, but here it is: Tauriga Sciences Inc (OTCMKTS:TAUG) is hot on the trail of a new...
Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) Releases Positive Results From Second Analysis Of NAV3-31 Phase 2B...
Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) has posted better results from NAV3-31 Phase 2B trial in patients, who are suffering from RA (Rheumatoid Arthritis). Interim analysis...
CymaBay Therapeutics Inc (NASDAQ: CBAY) Announces Promising Seladelpar Data In Treatment of Primary Biliary...
CymaBay Therapeutics Inc (NASDAQ: CBAY) has announced the presentation of promising seladelpar findings in primary biliary cholangitis (PBC) patients at The International Liver Congress...
MAKE IT MODERN
